Next Article in Journal
The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis
Next Article in Special Issue
Natural History of NAFLD
Previous Article in Journal
Relative Importance of Heart Failure Events Compared to Stroke and Bleeding in AF Patients
Previous Article in Special Issue
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Review

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?

Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Bialystok, 15-274 Bialystok, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Jérémie Gautheron
J. Clin. Med. 2021, 10(5), 924; https://doi.org/10.3390/jcm10050924
Received: 23 January 2021 / Revised: 8 February 2021 / Accepted: 16 February 2021 / Published: 1 March 2021
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which predispose to more serious hepatic conditions. It ranges from simple liver steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis, and even end-stage liver disease. Since obesity became one of the most important health concerns wordwide, a considerable increase in the prevalance of NAFLD and other metabolic implications has been observed, both in adults and children. Due to the coexistence of visceral obesity, insulin resistance, dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome (MetS). These relationships between NAFLD and MetS led to the set up in adults of a new term combining both of these conditions, called metabolic dysfunction-associated fatty liver disease (MAFLD). Based on these findings, we propose a set of criteria, which may be useful to diagnose MAFLD in children and adolescents. View Full-Text
Keywords: MAFLD; NAFLD; fatty liver; metabolic syndrome; obesity; children; nomenclature MAFLD; NAFLD; fatty liver; metabolic syndrome; obesity; children; nomenclature
Show Figures

Figure 1

MDPI and ACS Style

Flisiak-Jackiewicz, M.; Bobrus-Chociej, A.; Wasilewska, N.; Lebensztejn, D.M. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction? J. Clin. Med. 2021, 10, 924. https://doi.org/10.3390/jcm10050924

AMA Style

Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction? Journal of Clinical Medicine. 2021; 10(5):924. https://doi.org/10.3390/jcm10050924

Chicago/Turabian Style

Flisiak-Jackiewicz, Marta, Anna Bobrus-Chociej, Natalia Wasilewska, and Dariusz M. Lebensztejn 2021. "From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?" Journal of Clinical Medicine 10, no. 5: 924. https://doi.org/10.3390/jcm10050924

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop